Can analysts adopt a bullish outlook for Quidel Corporation (NASDAQ:QDEL)?

August 11, 2017 - By Winifred Garcia

 Can analysts adopt a bullish outlook for Quidel Corporation (NASDAQ:QDEL)?
Investors sentiment decreased to 0.8 in 2016 Q4. Its down 0.31, from 1.11 in 2016Q3. It dropped, as 8 investors sold Quidel Corporation shares while 36 reduced holdings. 8 funds opened positions while 27 raised stakes. 29.80 million shares or 0.16% less from 29.85 million shares in 2016Q3 were reported.
First Mercantile Tru holds 0.02% or 5,240 shares in its portfolio. Tower Limited Company (Trc) holds 100 shares or 0% of its portfolio. Fred Alger Management Inc owns 582,821 shares. Schwab Charles Investment Mngmt reported 114,102 shares. Moreover, Deutsche Bank & Trust Ag has 0% invested in Quidel Corporation (NASDAQ:QDEL). Howe & Rusling holds 0% or 600 shares. 1,843 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Jpmorgan Chase & Communication holds 607,392 shares. Alliancebernstein Lp stated it has 46,649 shares or 0% of all its holdings. Nationwide Fund has 208,245 shares for 0.02% of their portfolio. California Pub Employees Retirement Sys has 0% invested in Quidel Corporation (NASDAQ:QDEL) for 60,900 shares. Morgan Stanley invested 0% in Quidel Corporation (NASDAQ:QDEL). California State Teachers Retirement System, a California-based fund reported 55,368 shares. Royal National Bank & Trust Of Canada holds 0% in Quidel Corporation (NASDAQ:QDEL) or 1,875 shares. New York State Common Retirement Fund, a New York-based fund reported 890,655 shares.

Since February 24, 2017, it had 0 insider purchases, and 4 sales for $5.07 million activity. $834,204 worth of Quidel Corporation (NASDAQ:QDEL) shares were sold by BRYANT DOUGLAS C. Bujarski Robert Joseph also sold $1.05M worth of Quidel Corporation (NASDAQ:QDEL) shares.

Quidel Corporation (NASDAQ:QDEL) Ratings Coverage

Among 8 analysts covering Quidel (NASDAQ:QDEL), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Quidel had 19 analyst reports since September 2, 2015 according to SRatingsIntel. The company was maintained on Thursday, July 27 by Barclays Capital. Craig Hallum downgraded the shares of QDEL in report on Friday, October 23 to “Hold” rating. The rating was upgraded by Canaccord Genuity to “Buy” on Tuesday, July 18. The firm has “Outperform” rating given on Monday, June 13 by Raymond James. The firm has “Neutral” rating given on Friday, December 16 by Piper Jaffray. The firm has “Buy” rating given on Friday, January 8 by Canaccord Genuity. The stock has “Neutral” rating by PiperJaffray on Friday, December 16. The stock has “Outperform” rating by William Blair on Tuesday, July 18. Raymond James maintained it with “Outperform” rating and $41 target in Thursday, July 27 report. As per Wednesday, July 19, the company rating was maintained by Piper Jaffray. Below is a list of Quidel Corporation (NASDAQ:QDEL) latest ratings and price target changes.

27/07/2017 Broker: Raymond James Rating: Outperform Old Target: $36 New Target: $41 Maintain
27/07/2017 Broker: Barclays Capital Rating: Overweight Old Target: $36 New Target: $39 Maintain
19/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $35.0000 Maintain
17/07/2017 Broker: Barclays Capital Rating: Buy New Target: $30.0000
18/07/2017 Broker: William Blair Old Rating: Market Perform New Rating: Outperform Upgrade
18/07/2017 Broker: Canaccord Genuity Old Rating: Hold New Rating: Buy Upgrade
17/02/2017 Broker: CL King Rating: Neutral Initiate

The stock increased 2.45% or $0.8 during the last trading session, reaching $33.4. About 313,818 shares traded. Quidel Corporation (NASDAQ:QDEL) has risen 56.78% since August 11, 2016 and is uptrending. It has outperformed by 40.08% the S&P500.

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company has market cap of $1.12 billion. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. It currently has negative earnings. The Firm sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

More important recent Quidel Corporation (NASDAQ:QDEL) news were published by: Fool.com which released: “Here’s Why Quidel Corporation Is Rising Today” on July 18, 2017, also Seekingalpha.com published article titled: “Quidel announces definitive agreement to acquire Alere Triage Assets”, Seekingalpha.com published: “Quidel To Acquire Triage Assets From Alere Divestiture” on July 20, 2017. More interesting news about Quidel Corporation (NASDAQ:QDEL) was released by: Seekingalpha.com and their article: “Quidel Corporation’s (QDEL) CEO Doug Bryant on Q2 2017 Results – Earnings Call …” with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.